Plain language summary {#S0001}
======================

Causing deterioration of patient health and quality of life, fatigue is a prominent symptom of Parkinson's disease (PD). Measuring this symptom is relevant to the management of the disease, but doctors can only know about the presence and severity of fatigue through patients' reporting. The Parkinson's disease Fatigue Scale-16 items (PFS-16) was designed as self-applied scale ("patient-reported outcome," PRO) to measure and monitor the course of fatigue in a valid and reliable manner. The PFS-16 showed satisfactory metric properties and has been recommended for use in PD by a task force of the Movement Disorder Society.

The PFS-16 was developed for English-speaking populations, and it was validated in a cohort of PD patients. Translation, cross-cultural adaptation, and validation analyses are needed to make a PRO available to populations other than the one in which it was originally developed. As a result, researchers must explore and establish the equivalence between multiple versions of a clinical rating scale.

In the present study, the measurement properties of the PFS-16 were analyzed in a group of Spanish PD patients who were considered to have "advanced PD" and needed treatment with levodopa-carbidopa intestinal gel (LCIG). The characteristics of this sample made it convenient to check how the scale performs in this specific population, rather than in the general PD population. Using the methodology and statistical analyses relevant to this goal, the authors demonstrated that the PFS-16 performs as a feasible, reliable, valid, and sensitive measure of fatigue in advanced PD patients.

Introduction {#S0002}
============

While fatigue has been shown to affect 7--45% of the general population,[@CIT0001]--[@CIT0003] this crippling non-motor symptom is estimated to affect 33--58% of patients with Parkinson's disease (PD).[@CIT0004]--[@CIT0007] However, figures in some studies can be biased due to the challenging nature of defining this disorder.[@CIT0007],[@CIT0008] Even though there is no standardized definition of fatigue, despite its inclusion among the diagnostic criteria for both depression and anxiety in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition,[@CIT0007],[@CIT0009],[@CIT0010] specific criteria for diagnosing fatigue in PD have recently been proposed.[@CIT0008]

Although frequently confounded with depression and excessive sleepiness, fatigue has been shown to be related to anxiety, apathy, motor impairment, pain, and cognitive deficits, leading to drastic decreases in the health-related quality of life (QoL) of patients with PD.[@CIT0008],[@CIT0011]--[@CIT0014] Suggesting that it could be treated by increasing brain levels of serotonin and dopamine, fatigue has been linked both to the reduced serotonergic function in the basal ganglia and limbic areas of the brain and to the dopamine deficiency characteristic of PD.[@CIT0007],[@CIT0015],[@CIT0016] Yet, even though insights exist into its pathophysiology, fatigue is often overlooked and underdiagnosed in PD.[@CIT0017]

There are many generic rating scales to assess fatigue; however, the Parkinson's Fatigue Scale (PFS-16) is the only PD-specific scale.[@CIT0018] This patient-based, 16-item scale assesses the presence and severity of fatigue in PD patients, captures the physical aspects of fatigue and its impact on activities of daily living, and purposefully excludes fatigue's mental aspects. In previous studies, it has shown satisfactory internal consistency, stability, and construct validity,[@CIT0018]--[@CIT0024] and is recommended by the Movement Disorder Society Task Force.[@CIT0025]

Using its Spanish version, this study presents the first attempt to both validate the PFS-16 in patients with advanced PD (APD) and present data about responsiveness after a pharmacologic intervention.

Material and methods {#S0003}
====================

Design {#S0003-S2001}
------

The ADEQUA study (ClinicalTrials.gov Identifier: NCT02289729) focused on the treatment of APD using levodopa-carbidopa intestinal gel (LCIG). The data for the present study are derived from this national, multi-center study.[@CIT0026]

Patients {#S0003-S2002}
--------

Patients were included in the ADEQUA study for LCIG treatment by their neurologists if they were aged ≥18 years and had advanced levodopa-responsive PD with at least 2 hrs of daily "Off" time or 2 hrs of daily dyskinesia that could not be controlled by conventional treatment options. Participants were also required to be free from severe cognitive deterioration (Mini-Mental State Examination score ≥26).[@CIT0027]

If patients did not meet all inclusion criteria, were not compatible with LCIG treatment according to the drug fact sheet, or did not display appropriate cognitive functioning (Mini-Mental State Examination score \<26), they were excluded from the study.

The estimated sample size to achieve the objectives of the ADEQUA study was a minimum of 60 patients. This sample was recruited from November 2014 to April 2016 from several hospitals throughout Spain. A minimal sample of 50 patients was deemed acceptable for the validation study.[@CIT0028]

Assessments {#S0003-S2003}
-----------

Demographic data for sex, age, ethnicity, marital status, employment, education, time from PD diagnosis, and current treatment were collected.

The Parkinson's Fatigue Scale is a 16-question inventory used to screen for the presence and severity of fatigue in PD patients over the past two weeks. Each item ranges between one ("strongly disagree") and five ("strongly agree"). While there are three ways to calculate the total score for this clinical instrument,[@CIT0029] the method chosen for the present study was summing all the items because evidence suggests that the dichotomized scoring of the PFS-16 limits the precision and accuracy of this tool.[@CIT0030]

Besides the PFS-16, patients were assessed in the "on" state during this study with the following instruments:

Unified Parkinson's Disease Rating Scale (UPDRS)[@CIT0031] parts III (motor examination) and IV (therapy complications). Part III is composed of 14 items, but there are 27 scores as each item assesses multiple parts of the body. Each score ranges from from 0 (normal) to 4 (severe), and the total score can be between 0 and 108. Part IV includes 11 items (four for dyskinesias, four for fluctuations, and 3 items for other complications), with some items scoring from 0 to 4 and others 0 (no) to 1 (yes). The total score for Part IV ranges from 0 to 23.

Schwab and England Scale (S&E).[@CIT0032] This frequently used, 11-stage scale evaluates the ability to complete activities of daily living in PD patients and meets "recommended" criteria for use in PD.[@CIT0033] Scores range from 0% (completely dependent with vegetative dysfunction, bedridden) to 100% (completely independent, essentially normal).

Hoehn and Yahr (HY).[@CIT0034] This five-level classification system ranks the stages of a patient's disease progression from one ("unilateral involvement only usually with minimal or no functional disability") to five ("confinement to bed or wheelchair unless aided").

Non-motor Symptoms Scale (NMSS).[@CIT0035] The NMSS is a 30-item instrument used to evaluate the burden of non-motor symptoms in PD. This scale is divided into nine domains: cardiovascular, sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, gastrointestinal tract, urinary function, sexual function, and miscellaneous.

Clinical Global Impression--Severity Scale (CGI-S).[@CIT0036] This is a generic, seven-point scale used to rate the severity of a patient's disease state at a given time. This scale ranges from one ("normal/not at all ill") to seven ("among the most extremely ill patients").

Beck Anxiety Inventory (BAI).[@CIT0037] Using 21 items, the BAI determines the severity of anxiety over the past week. The total score is calculated by summing the items, which are scored from zero ("not at all") to three ("severely -- it bothered me a lot"). More severe anxiety symptoms are indicated by higher scores.

Beck Depression Inventory II (BDI-II).[@CIT0038] Also composed of 21 items that are scored from zero to three, this inventory measures the severity of depression over the past three weeks. Its total score is calculated by summing the patient's responses to each item. More severe depressive symptoms are expressed with higher BDI-II scores.

Apathy Scale (AS).[@CIT0039] This 14-question instrument screens and assesses the severity of apathy in PD patients over the past four weeks. Each question is scored from zero ("not at all") to three ("a lot"), and the total score is calculated by adding the scores from questions 1--8 to the inverse scores from questions 9--14. According to the AS developers, the cutoff score for apathy is 13/14.[@CIT0039]

Parkinson's Disease Questionnaire-39 items (PDQ-39).[@CIT0040] This patient-completed assessment determines the impact of PD on QoL. It consists of 39 questions separated into eight domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort.

Zarit Burden Interview (ZBI).[@CIT0041] The ZBI assesses the burden experienced by caregivers of dependent persons with various medical disorders, and it has been validated for caregivers of PD patients.[@CIT0042] This 22-item inventory is scored from one ("never/nothing") to five ("almost always/extremely"), and its total score is calculated by summing the responses to represent a caregiver's overall burden.

Levodopa equivalent daily dose (LEDD) was calculated for each patient according to Tomlinson et al[@CIT0043].

Ethical issues {#S0003-S2004}
--------------

The study was conducted in accordance with the Declaration of Helsinki and with standard operating procedures that guaranteed compliance with Good Clinical Practice, as described in the ICH guidelines. The study was evaluated by the Spanish Agency of Medicines and Medical Devices, and it was approved by the Spanish Autonomous Communities and the Ethics Committees of the participant hospitals. Patients signed their informed consent before inclusion in the study.

Data analysis {#S0003-S2005}
-------------

Data were anonymized and sent to the National Center Epidemiology at the Carlos III Institute of Health in Madrid, Spain, for analysis. Using the Shapiro-Francia test, it was determined that non-parametric statistics were required for this analysis. Descriptive statistics (measures of central tendency and frequency percentages) were applied to socio-demographic, historical, and evaluative data.

For each item of the PFS-16 and its total score, statistics regarding data quality and acceptability were calculated. These statistics included the percentage of computable scale scores, mean, median, standard deviation, skewness, minimum and maximum values, and floor and ceiling effects. To consider data quality and acceptability satisfactory, missing data should comprise \<5% of the data set,[@CIT0044] all possible scores should be observed in the sample, the mean and median of the scale total score should be close (difference of \<10% of maximum possible score),[@CIT0045] floor and ceiling effect should be \<15%,[@CIT0046] and the skewness values for both items and total score should range from −1 to +1.[@CIT0047]

An exploratory factor analysis based on polychoric correlations (due to the non-normality of data according to Mardia's test) and robust unweighted least squares for factor extraction was performed. Bartlett's sphericity test and Kaiser-Meyer-Olkin statistic were applied to determine the sample adequacy. In addition, an optimal implementation of parallel analysis for determining the number of dimensions was carried out.

Using Cronbach's alpha, corrected item-total correlation, and item homogeneity, internal consistency was analyzed. Standard values used for these statistics are: Cronbach's alpha \>0.70,[@CIT0048] corrected item-total correlation ≥0.30,[@CIT0047] and item homogeneity coefficient ≥0.15.[@CIT0049]

Convergent validity of the PFS-16 total score with the domains and total scores of the other instruments used in this study was assessed using Spearman's rank correlation coefficients (r~S~). Coefficient values of 0.30 to 0.59 were deemed moderate correlations, and values ≥0.60 were deemed high correlations.[@CIT0050]

To analyze the differences between groups of sex, age, time from diagnosis, HY stage, and CGI-S in reference to PFS-16 total score, Mann-Whitney and Kruskal-Wallis tests were applied. Significant differences were determined using the magnitude of difference and *p*-values.[@CIT0051]

PFS-16 responsiveness was analyzed using data from baseline and follow-up 6±0.5 months later. The magnitude of difference, relative change (percentage of change), standard error of the difference ($\documentclass[12pt]{minimal}
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\end{document}$),[@CIT0052] and effect size for paired samples data[@CIT0053] were applied. Cohen's *d* of 0.20--0.49, 0.50--0.79, and ≥80 were considered weak, moderate, and strong, respectively.[@CIT0054] The relationship between changes in PFS-16 total score and the total scores of the other instruments utilized in this study were assessed using Spearman's rank correlation coefficients.

This data analysis was carried out according to the Consensus‐based standards for the selection of health measurement instruments (COSMIN)[@CIT0055],[@CIT0056] using IBM SPSS (Version 24).

Results {#S0004}
=======

The baseline characteristics of the sample are described in [Table 1](#T0001){ref-type="table"}. In [Table 2](#T0002){ref-type="table"}, the descriptive statistics for the applied measures are summarized.Table 1Clinical and socio-demographic characteristics of patients at baselineBaseline characteristics (n=61)**Age, years** (mean ± SD)\
LL-UL68.02±7.43\
50--81**Sex, male** (%)60.7**Duration of the disease**, years (mean ± SD)\
LL-UL12.57±5.97\
4--37**Marital status**Married/Partnered (%)77.1**Level of education**\
Basic or lesser (%)\
77.0**Employment status (%)**\
Retired\
Never worked before\
Off sick\
Others\
78.7\
13.0\
4.9\
3.3**Hoehn & Yahr**, median (IQR)\
Stage 1 (%)\
Stage 2 (%)\
Stage 3 (%)\
Stage 4 (%)2 (1--2)\
44.26\
42.62\
11.48\
1.64**CGI-S** (median)\
Score 1 (%)\
Score 2 (%)\
Score 3 (%)\
Score 4 (%)3\
1.64\
8.20\
75.41\
14.75[^1] Table 2Descriptive statistics of measures in the studyMeasuresMeanSDMinMax**UPDRS -- Motor Examination**30.0514.06458**UPDRS -- Complications**8.622.87315**Schwab and England Scale (ON)**69.8423.7710100**Non-Motor Symptoms Scale--**Total Score83.0532.0729167 Cardiovascular (including falls)2.413.53014 Sleep/fatigue16.877.63040 Mood/cognition15.6913.93056 Perceptual problems/hallucinations3.085.53025 Attention/memory5.806.11024 Gastrointestinal tract7.446.23024 Urinary12.449.59036 Sexual function7.808.16024 Miscellaneous11.518.68036**Beck Anxiety Inventory**19.779.24041**Beck Depression Inventory**18.119.34146**Apathy Scale**11.696.67124**PDQ-39--**Summary Index46.1313.8110.9085.90 Mobility66.8822.312.50100.00 Activities of daily living54.6524.484.1795.83 Emotional well-being47.9221.704.17100.00 Stigma20.1022.61093.75 Social support18.8924.490100.00 Cognitions36.3520.89093.75 Communication31.8124.670100.00 Bodily discomfort45.6920.730100.00**Zarit Burden Interview**25.3013.47464**Levodopa equivalent daily dose**1455.98456.00478.003110.00[^2]

Two patients (3.3%) were excluded from the analysis due to a lack of responses on the PFS-16; the reasons for this lack of response are unknown. In the remaining sample, 0.31% of the data was missing, but these values were imputed using the mean of the patient's observed values. Disregarding PFS-16 item 3, in which no patient chose a score of 1, all possible scores were observed in the sample. Item standard deviation ranged from 0.82 to 1.31, floor effects stayed within the standard range for all items, and there were moderate-to-high ceiling effects for most items. Almost all values remained within the accepted range of skewness or were marginally outside (up to an excess of \|0.55\| points). The PFS-16 total score had a mean and standard deviation of 58.71±12.43, a median of 61.0, a range of 18 to 78, negligible floor and ceiling effects of 1.7% each, and skewness of −0.84 ([Table 3](#T0003){ref-type="table"}).Table 3Acceptability data of the Parkinson's Fatigue ScaleItemMinMaxMeanSDMedianFloorCeilingSkewness1. I have to rest during the day154.021.084.003.4%40.7%−1.072. My life is restricted by fatigue153.641.264.008.5%27.1%−0.803. I get tired more quickly254.250.824.000.0%44.1%−1.094. One of my three worst symptoms153.631.164.005.1%25.4%−0.605. I feel completely exhausted153.161.113.005.2%10.3%−0.086. Makes me reluctant to socialize153.341.314.0012.1%19.0%−0.487. It takes me longer to do things153.801.184.008.6%27.6%−1.178. I have a feeling of heaviness153.741.094.005.2%24.1%−0.919. If I wasn't tired, I could do more154.240.944.001.7%45.8%−1.5510. Everything I do is an effort153.760.994.003.4%22.0%−0.8311. I feel tired for much of the time153.921.024.001.7%30.5%−0.9312. I feel totally drained152.901.283.0016.9%10.2%−0.0113. Difficult coping w/daily activities153.710.994.003.4%17.2%−0.9414. Tired but I haven't done anything153.551.114.006.9%15.5%−0.8515. I do less than I would like154.000.994.001.7%36.2%−0.9016. Want to lay down wherever I am153.121.243.0010.3%15.5%−0.07**Total score**187858.7112.4361.001.7%1.7%−0.84[^3]

The exploratory factor analysis showed two factors explaining 67% of the variance (Bartlett's statistic, *p*=0.00001; Kaiser-Meyer-Olkin test =0.87). The first factor (57.7% of the variance) of the unrotated matrix included all items of the scale, with loads ≥0.58, and the parallel analysis advised considering only one dimension.

Cronbach's alpha was 0.93, and item homogeneity was 0.19; both were greater than the minimum accepted values of 0.70 and 0.15, respectively. Similarly, all corrected item-total correlations were greater than the standard value of 0.30 ([Table 4](#T0004){ref-type="table"}).Table 4Corrected item-total correlationsItemCoefficient^a^1. I have to rest during the day0.532. My life is restricted by fatigue0.613. I get tired more quickly than others0.504. One of my three worst symptoms0.785. I feel completely exhausted0.676. Makes me reluctant to socialize0.557. It takes me longer to do things0.768. I have a feeling of heaviness0.579. If I wasn't so tired, I could do more0.5910. Everything I do is an effort0.7011. I feel tired for much of the time0.6912. I feel totally drained0.5213. Difficulty coping w/daily activities0.7814. Tired but I haven't done anything0.8415. I do less than I would like0.8016. I want to lay down wherever I am0.65[^4]

In terms of convergent validity, the PFS-16 showed a strong correlation with item 20 of the BDI-II ("tiredness or fatigue," r~S~=0.65) and a moderate correlation with item 4 of the NMSS (fatigue or lack of energy, r~S~=0.33). Furthermore, it had moderate correlations with the BAI (r~S~=0.30), BDI-II (r~S~=0.48), and PDQ-39 summary index (r~S~=0.36) and a weak correlation with the AS (r~S~=0.26). Regarding the PDQ-39 domains, the PFS-16 had moderate correlations with social support (r~S~=0.31), cognitions (r~S~=0.35), and communication (r~S~=0.32) and weak ones with the rest (r~S~=0.10--0.29). However, the PFS-16 was not significantly correlated with the other measures in the study, including LEDD ([Table 5](#T0005){ref-type="table"}). When considering groups categorized by age (≤60, 61--70, ≥71 years), sex, marital status, education level, time from diagnosis (\<10, 10--15, \>15 years), HY, and CGI-S, there were no significant differences in PFS-16 total score among them. There was a significant difference between retired patients (79%) and the combination of other employment status (21%; [Table 1](#T0001){ref-type="table"}): 56.74±12.46 vs 66.25±9.28 (Mann-Whitney test, *p*=0.01).Table 5Correlation between the Parkinson Fatigue Scale and other measuresCoefficient^a^**Unified Parkinson's Disease Rating Scale III**−0.03**Unified Parkinson's Disease Rating Scale IV**0.12**Schwab and England Scale (ON)**0.04**Item 4 of the Non-Motor Symptoms Scale^b^**0.33**Non-Motor Symptoms Scale --** Total Score0.18 Cardiovascular (including falls)0.20 Sleep/fatigue0.21 Mood/apathy0.08 Perceptual problems/hallucinations0.15 Attention/memory0.25 Gastrointestinal tract0.03 Urinary0.06 Sexual function0.01 Miscellaneous0.05**Beck Anxiety Inventory**0.30**Item 20 of the Beck Depression Inventory^b^**0.65**Beck Depression Inventory**0.48**Apathy Scale**0.13**PDQ-39 --** Summary Index0.36**Zarit Burden Interview**0.04**Levodopa equivalent daily dose**0.23[^5]

After treatment, significant improvements in the conditions assessed by the clinical measures applied in this study are apparent, except the social support domain of the PDQ-39 and the ZBI ([Table 6](#T0006){ref-type="table"}).Table 6Differences in assessments between baseline and follow-upTotal scoreBaselineFollow-upMeanSDMinMaxMeanSDMinMax*p*-value^a^**PFS-16**60.1711.48327849.6014.401676\<0.001**UPDRS III**29.0413.8245522.8911.552440.001**UPDRS IV**8.562.663134.362.42011\<0.001**Non-Motor Symptoms Scale**83.8333.352916748.1329.793124\<0.001**Beck Anxiety Inventory**20.129.7204113.6010.39142\<0.001**Beck Depression Inventory**18.459.7114612.6410.310490.003**Apathy Scale**11.696.6712412.346.521250.460**PDQ-39**46.7413.5910.985.933.6616.874.4972.44\<0.001**Zarit Burden Interview**24.2713.6746424.4014.281610.603[^6]

The standard error of the difference between baseline-follow-up on PFS-16 total score over this 6-month period was 4.3, the relative change was −17.6%, and the effect size was 0.92. Correlations between the changes in the other assessments and the PFS-16 were generally weak or lesser, except for BDI (r~S~=0.58); NMSS domain 3: mood/apathy (r~S~=0.49) and total score (r~S~=0.38); and PDQ-39 mobility (r~S~=0.57), emotional well-being (r~S~=0.44), cognitions (r~S~=0.30), bodily discomfort (r~S~=0.47), and total score (r~S~=0.60).

Discussion {#S0005}
==========

The PFS-16 has already been validated in several countries;[@CIT0018]--[@CIT0024] however, this study presents the first attempt to validate the scale in APD patients using the Spanish version.

In this study, data quality was considered acceptable, as only two patients were excluded due to a lack of data and because imputation needed to be applied to only 0.3% of the data. However, other studies reported no missing data ([Table 7](#T0007){ref-type="table"}).[@CIT0019],[@CIT0021],[@CIT0022] This difference could be related to the advanced condition of patients in the present study, although other reasons are plausible.Table 7Summary of the clinimetric attributes explored for the PFS-16\*Brown 2005Kummer 2011Hagell 2012Fu 2017Ozturk 2018Çilga 2018Dagklis 2019Present 2019*Reference***18192021222324--**Missing dataNoNoNo0.3%**Scaling assumptions**SS**Feasibility/Acceptability** Floor effectNoNoNoNo Ceiling effectNoNoNoNo SkewnessSS**Structure - Factors**1112**Internal Consistency** Cronbach's alphaSSSSSSS Inter-item correlationSSS Item-total correlationSSSSS**Convergent Validity** FatigaHHHHHHM/H UPDRS, HYMLLLL/ML DepressionHHMLM AnxietyHMLM ApathyL Sleep (ESS)ML CognitionLLLL Quality of LifeMHM**Correlation or Known-groups validity** AgeLLLLLNo SexNo PD durationLLLLNo Education levelLLNo LEDDLLLL**Sensitivity to change**S[^7]

Almost all possible values were observed in the sample (except for a score of 1 on item 3), and the relationship between the mean, median, and closeness of item standard deviations were consistent throughout, as was observed in other studies.[@CIT0020],[@CIT0021]

While the floor effects remained within the standard range for all items, the ceiling effect was moderate-to-high for most and the skewness values slightly exceeded the standard range in several items. However, the PFS-16 total score displayed negligible floor and ceiling effects and a skewness value within the standard range ([Table 3](#T0003){ref-type="table"}). Therefore, it can be concluded that the scale contains appropriate feasibility and acceptability -- a finding consistent with previous validation studies ([Table 7](#T0007){ref-type="table"}).[@CIT0019]--[@CIT0021]

In agreement with the confirmatory analysis of previous studies,[@CIT0018],[@CIT0022],[@CIT0023] our exploratory factor analysis showed results compatible with the unidimensional nature of the PFS-16, including the amount of variance explained (67% vs 64%).

Furthermore, as measured by Cronbach's alpha, the internal consistency for the scale in our study (0.93) was in line with those found in previous studies.[@CIT0018]--[@CIT0024] Similarly, corrected item-total correlations ([Table 4](#T0004){ref-type="table"}) overlap previous findings.[@CIT0020]--[@CIT0023] Item homogeneity (r~S~=0.19) was found to satisfy the accepted value of ≥0.15, indicating sufficient association among the items.[@CIT0019],[@CIT0022] As a whole, our results demonstrate adequate scaling assumptions and internal consistency for the PFS-16 in APD.

Like Hagell et al[@CIT0049] and others,[@CIT0021],[@CIT0022] we found a weak correlation between the PFS-16 and UPDRS III and IV, whereas a moderate correlation was obtained by other researchers.[@CIT0019],[@CIT0023]

Since our analysis, to our knowledge, was the first to be conducted using a sample of APD patients using the PFS-16 and AS, it is challenging the draw conclusions from these results. While significant associations have been found between apathy and fatigue in some studies,[@CIT0057]--[@CIT0061] our study and others have shown a loose relationship between these two non-motor symptoms, which are separate disorders ([Table 5](#T0005){ref-type="table"}).[@CIT0008],[@CIT0017],[@CIT0062],[@CIT0063]

Nonetheless, the PFS-16 did moderately correlate with BAI and BDI-II, suggesting that fatigue is related to anxiety and depression in PD patients. The highest correlation was found between the PFS-16 and BDI-II item 20, which directly inquired about tiredness and fatigue. In other studies, low-to-high correlations were found between the PFS-16 and depression measures,[@CIT0019]--[@CIT0022] and similar findings are observed between the fatigue scale and anxiety assessments.[@CIT0019],[@CIT0021],[@CIT0022] As a whole, these findings suggests that PFS-16 does not discriminate between pure symptoms of fatigue and disorders like anxiety and depression.

Furthermore, the PFS-16 was moderately correlated with item 4 of the NMSS (r~S~=0.33), which directly asked about fatigue or lack of energy. A measure of daytime sleepiness was not included, and this deficit is recognized as a limitation in the present study due to the potential overlap between fatigue and sleepiness.

Prior research has shown that anxiety, depression, and fatigue are negatively associated with QoL and are extensively-comorbid non-motor symptoms of PD.[@CIT0006],[@CIT0013],[@CIT0064],[@CIT0065] As such, our study found a moderate correlation between PFS-16 and PDQ-39 summary index and with its domains of social support, cognitions, and communication, suggesting an association of these factors with fatigue's effect on QoL in APD. Other studies have found a moderate or close relationship between PFS-16 and QoL measures,[@CIT0022],[@CIT0024],[@CIT0066],[@CIT0067]

We found that sex, age, education level, time from diagnosis, HY, LEDD, and CGI-S were not related to the presence or severity of fatigue -- findings shared with other studies and indicative of a weak discriminant validity of the scale for these groupings.[@CIT0019]--[@CIT0023],[@CIT0058] Marital status showed no significant differences in the PFS-16 total score. A significant difference was found between retired and other employment status, but the meaning of this finding is uncertain given the diversity of situations included in the latter group and its small size.

With an acceptable precision value, a strong effect size, and a sizable percentage of relative change, the PFS-16 demonstrated satisfactory performance and reliability following longitudinal analysis. Specifically, this can be derived from the standard error of the difference value, which was around one-third of the baseline standard deviation.

Longitudinal analysis even showed weak-to-moderate correlations with changes in several of the clinical assessments applied in this study -- namely, BDI-II; NMSS domain 3 and total score; and PDQ-39 total score and its domains of mobility, emotional well-being, cognitions, and bodily discomfort. This would suggest a potential relationship between the improvement of fatigue and these other aspects. It was also found that, following LCIG treatment, PFS-16 total score was significantly lower (four times the SED; a large effect size) -- a finding consistent with another clinical trial that found improvement of physical fatigue with levodopa.[@CIT0015]

This study has, at least, two relevant limitations: the relatively small sample size and the use of data from a study not designed for the validation of the PFS-16. Nonetheless, it provides information on the responsiveness of this scale and its performance in a scenario not previously explored (APD).

Conclusions {#S0006}
===========

Fatigue is a disabling non-motor symptom of PD that severely deteriorates patients' ability and QoL. Therefore, it is necessary to have valid clinical tools to assess fatigue in PD. The present study found that the Spanish version of PFS-16, as a whole, possesses satisfactory acceptability, reliability, construct validity, and responsiveness in the assessment of physical fatigue in patients with APD.

Abbreviation list {#S0007}
=================

APD, Advanced Parkinson's disease; AS, Apathy scale; BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; LCIG, Levodopa-Carbidopa Intestinal Gel; CGI-S, Clinical Global Impression--Severity; HY, Hoehn & Yahr stage; LEDD, Levodopa equivalent daily dose; NMSS, Non-Motor Symptoms Scale; PD, Parkinson's disease; PDQ-39, Parkinson's Disease Questionnaire-39 items; PFS-16, Parkinson's Fatigue Scale; QoL, Health-related quality of lifep; S&E, Schwab and England Scale; UPDRS, Unified Parkinson's Disease Rating Scale; ZBI, Zarit Burden Inventory.
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[^1]: **Abbreviations:** LL, lower limit; UL, upper limit: SD, standard deviation; IQR, interquartile range.

[^2]: **Abbreviations:** Max, maximum; Min, minimum; PDQ-39, Parkinson's Disease Questionnaire-39 items; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale.

[^3]: **Abbreviations:** Max, maximum; Min, minimum; SD, standard deviation.

[^4]: **Note:** ^a^Spearman's rank correlation coefficient.

[^5]: **Notes:** ^a^Spearman's rank correlation coefficient. ^b^Fatigue-specific items.

    **Abbreviations:** PDQ-39, Parkinson's Disease Questionnaire-39 items.

[^6]: **Note:** ^a^Wilcoxon test.

    **Abbreviations:** PDQ-39, Parkinson's Disease Questionnaire-39 items; PFS-16, Parkinson's Fatigue Scale; UPDRS, Unified Parkinson's Disease Rating Scale.

[^7]: **Note:** \*Test-retest reliability has also been analyzed and found satisfactory in several of these studies.

    **Abbreviations:** UPDRS, Unified Parkinson's Disease Rating Scale; HY, Hoehn and Yahr staging; ESS, Epworth Sleep Scale; PD, Parkinson's disease; LEDD, Levodopa equivalent daily dose; S, Satisfactory; L, Low; M, Moderate; H, High.
